Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

David Hewitt(Glasgow Royal Infirmary), Tony W. Ho(Johns Hopkins University), Robert Bachman(Merck & Co., Inc., Rahway, NJ, USA (United States)), David W. Dodick(New York Academy of Medicine), Sheena K. Aurora(Impel Neuropharma (United States)), Donna Taraborelli(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yang Ge(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher Lines(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter J. Goadsby(King's College London), Christopher Assaid(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaoyin Fan(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cephalalgia
March 7, 2011
10.1177/0333102411398399
Cited by 263

Related Papers

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
|Pain|2003|3.5k
Advances in Neuropathic Pain
|Archives of Neurology|2003|1.2k
Sources of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation
|American Journal of Clinical Nutrition|1979|997
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
|Annals of Neurology|1999|890
MALIGNANT DISEASE IN CHILDHOOD AND DIAGNOSTIC IRRADIATION IN UTERO
|The Lancet|1956|569